Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Alnylam Pharmaceuticals's operating assets for the quarter that ended in Mar. 2026 was $2,120 Mil. Alnylam Pharmaceuticals's operating liabilities for the quarter that ended in Mar. 2026 was $2,781 Mil. Alnylam Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 was $4,966 Mil. Therefore, Alnylam Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was -0.13.
Alnylam Pharmaceuticals Scaled Net Operating Assets Related Terms
Alnylam Pharmaceuticals Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Alnylam Pharmaceuticals's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals Scaled Net Operating Assets Chart
LTS:0HD2 vs RVMD, ONC, MRNA: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Alnylam Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of -0.13 mean?
Alnylam Pharmaceuticals (LTS:0HD2) has a Scaled Net Operating Assets of -0.13 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Alnylam Pharmaceuticals and its competitors.
Is Alnylam Pharmaceuticals' Scaled Net Operating Assets too high?
Alnylam Pharmaceuticals' current Scaled Net Operating Assets is -0.13. Overall, Alnylam Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Scaled Net Operating Assets compare to RVMD and ONC?
Alnylam Pharmaceuticals' Scaled Net Operating Assets of -0.13 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Alnylam Pharmaceuticals and its competitors. Alnylam Pharmaceuticals's current Scaled Net Operating Assets is -0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $507.34, compared to a current price of $297.28 — trading 41.4% below its estimated fair value. The current Scaled Net Operating Assets is -0.13. Alnylam Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Scaled Net Operating Assets is -0.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of $297.28 is trading 41.4% below its estimated GF Value™ of $507.34.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for LTS:0HD2:
Scaled Net Operating Assets: -0.13
GF Value™: $507.34 vs. price of $297.28 (41.4% below fair value)
No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
67GF Score
Get the complete analysis for LTS:0HD2
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HD2 has been successfully added to your 
